

Revision: HCFA-PM-93-3 (MB)  
April 1993

OMB No.

State/Territory: Arizona

The State is in compliance with the new drug review and utilization requirements set forth in section 1902(o) of the Act, as follows:

1902(a)(85) and Section 1004 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act)

**1. Claim Review Requirements**

- a. The following Safety Edits have been implemented at the Point-of-Sale including Early, Dosage, Duplicate, and Quantity Limits:
  - i. The state has implemented the following prospective opioid safety edits:
    - (1) Quantity limits, including days' supply limits;
    - (2) Length of therapy limits;
    - (3) Refill frequency (percent to refill) limits;
    - (4) Duplicate fills; and
    - (5) Maximum Morphine Milligram Equivalents (MME) per Day Limits.
  - ii. The state has implemented the following retrospective opioid safety reviews:
    - (1) Quantity limits, including days' supply limits;
    - (2) Length of therapy limits;
    - (3) Refill frequency (percent utilized to refill) limits;
    - (4) Duplicate fills; and
    - (5) Maximum MME/ Day reviews.

**2. Concurrent Utilization Alerts**

- a. Opioid and Benzodiazepines Current Fill Reviews
  - i. The state has implemented and monitors results of Point-of-Sale alerts for concomitant use of opioids and benzodiazepines.
- b. Opioid and Antipsychotic Concurrent Fill Reviews
  - i. The state has implemented and monitors results of Point-of-Sale alerts for concomitant use of opioids and antipsychotics.

TN No.

Supersedes

Approval Date: \_\_\_\_\_

Effective Date: October 1, 2019

TN No. NEW

Revision: HCFA-PM-93-3 (MB)  
April 1993

OMB No.

State/Territory: Arizona

c. Opioid and Antipsychotic and Benzodiazepine Current Fill Reviews

(i)The state has implemented and monitors results of Point-of-Sale alerts for concomitant use of opioids with an Antipsychotic and a Benzodiazepine.

**3. Program to Monitor Antipsychotic Medication Use by Children**

- a. The state has implemented and monitors the following:
- i. Age restrictions;
  - ii. Quantity limits;
  - iii. Prior authorization for duplicate therapy; and
  - iv. Medication use in Foster Children.

**4. Fraud, Waste and Abuse Identification.**

- a. The State has implemented policy requirements and monitors the results including but not limited to the following:
- i. Number of opioid prescribers per member;
  - ii. Number of pharmacies utilized per member for opioid fills;
  - iii. Prior authorization requirements for long acting opioids;
  - iv. Controlled Substances Prescription Monitoring Program, the State's PDMP, review for all prior authorization requests for opioids; and
  - v. Controlled and Non-Controlled Utilization including the following:
    1. Atypical Antipsychotics;
    2. Benzodiazepines;
    3. Hypnotics;
    4. Muscle Relaxants;
    5. Opioids
    6. Stimulants; and
    7. Others as identified.

---

TN No.

Supersedes Approval Date: \_\_\_\_\_

Effective Date: October 1, 2019

TN No. NEW